Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lornoxicam

X
Drug Profile

Lornoxicam

Alternative Names: Bosporon; Chlortenoxicam; HN 10000; RO 139297; Safem; TS 110; Xefo

Latest Information Update: 08 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer POZEN; Takeda Pharmaceuticals International GmbH
  • Class Antirheumatics; Nonsteroidal anti-inflammatories; Small molecules; Thiazines
  • Mechanism of Action Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neuropathic pain; Osteoarthritis; Pain; Postoperative pain; Rheumatic disorders
  • Discontinued Migraine

Most Recent Events

  • 06 Feb 2019 Aralez Pharmaceuticals is now called Old API Wind-down
  • 17 Aug 2017 Lornoxicam market licensed to Hikma Pharmaceuticals in Middle East and North Africa
  • 29 Mar 2012 Nycomed is now called Takeda Pharmaceuticals International
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top